NCT03397030 is a NA clinical trial of Home-Based Exercise Program in Prostatic Neoplasm, sponsored by The University of Texas Health Science Center at San Antonio.

Who is sponsoring NCT03397030?

NCT03397030 is sponsored by The University of Texas Health Science Center at San Antonio.

What drugs are being tested in NCT03397030?

Interventions in NCT03397030: Home-Based Exercise Program.

What condition does NCT03397030 study?

NCT03397030 studies Prostatic Neoplasm.

Is NCT03397030 still recruiting?

NCT03397030 is currently completed. Last updated 10 August 2021.

Last reviewed 2021-08-10 · How we verify

NCT03397030

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Impact of Exercise on Prognostic Biomarkers Related to Prostate Cancer

Completed NA Last updated 10 August 2021

What this trial tests

NA trial testing Home-Based Exercise Program in Prostatic Neoplasm in 27 participants. Completed in 19 November 2020.

Timeline

5 January 2017

Primary endpoint
9 July 2020

19 November 2020

Quick facts

Lead sponsor	The University of Texas Health Science Center at San Antonio
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	27
Start date	5 January 2017
Primary completion	9 July 2020
Estimated completion	19 November 2020
Sites	2 locations across United States

Drugs / interventions tested

Home-Based Exercise Program

Conditions studied

Prostatic Neoplasm — all drugs for Prostatic Neoplasm →

Sponsor

The University of Texas Health Science Center at San Antonio

Who can join

40 and older, male only, with Prostatic Neoplasm. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The goal of this study is to demonstrate the impact of a home based exercise program versus wait-list control to modulate circulating prognostic biomarkers in men with prostate cancer under active surveillance.

Publications & conference data

3 peer-reviewed publications reference this trial (live from Europe PMC):

Pilot Study on the Impact of a Home-Based Exercise Program on Inflammatory Cytokines and Quality of Life in Men with Prostate Cancer Under Active Surveillance.
Moon C, Gallegos AM, Sheikh B, Kumar P, et al · · 2022 · cited 8× · PMID 36200522 · DOI 10.1177/10732748221130964
A Holistic Approach to Hard-to-Treat Cancers: The Future of Immunotherapy for Glioblastoma, Triple Negative Breast Cancer, and Advanced Prostate Cancer.
Puig-Saenz C, Pearson JRD, Thomas JE, McArdle SEB. · · 2023 · cited 4× · PMID 37626597 · DOI 10.3390/biomedicines11082100
A randomized controlled trial of a home-based exercise program on prognostic biomarkers in men with prostate cancer: A study protocol.
Patel DI, Gallegos AM, Sheikh B, Vardeman S, et al · · 2020 · cited 1× · PMID 33083630 · DOI 10.1016/j.conctc.2020.100659

Verify or expand the search:

Other trials of Home-Based Exercise Program

Trials testing the same drug.

NCT07198750 — "Bimodal vs Unimodal High-Intensity Pulsed Electromagnetic Field Therapy in Older Adults With Knee Osteoarthritis" · NA · recruiting
NCT06176846 — Immersive Virtual Reality Exergaming Program in Adolescents Diagnosed With Juvenile Idiopathic Arthritis · NA · unknown
NCT07372534 — Efficacy of Craniosacral Therapy in Patients With Gonarthrosis · NA · completed

Other recruiting trials for Prostatic Neoplasm

Currently open trials in the same condition.

NCT07084779 — Investigation of Impact of AI on Prostate Cancer Workflow · NA · recruiting
NCT05968144 — Towards Understanding Between ADT Treatment, Circadian Rhythm, and Physiological Responsiveness · Phase 1, PHASE2 · active not recruiting
NCT05849298 — A Phase II Study of AAA617 Alone and AAA617 in Combination With ARPI in Patients With PSMA PET Scan Positive CRPC · Phase 2 · active not recruiting
NCT06292897 — Using Tissue-based Spatial Data to Understand How Obesity-related Tumor Metabolites Fuel Prostate Cancer Progression · recruiting
NCT06046131 — Clinical, Genetic and Environmental Determinants of Prostate Cancer Progression. · NA · recruiting

Other The University of Texas Health Science Center at San Antonio trials

Trials by the same sponsor.

NCT07280897 — SCIPI Implementation and Evaluation: A Multi-site Proof-of-Concept Pilot Trial · NA · not yet recruiting
NCT07053319 — SGLT2i, Pioglitazone, and Ketone Production in T2D · Phase 1 · recruiting
NCT07056699 — SGLT2i, Pioglitazone, and Ketone Production in T1D · Phase 3 · not yet recruiting
NCT06609343 — Bupropion for Fatigue in End-stage Kidney Disease Patients on Hemodialysis · Phase 1, PHASE2 · not yet recruiting
NCT07437053 — Sarcopenia in Chronic Kidney Disease (CKD) Patients · EARLY_PHASE1 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03397030 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by The University of Texas Health Science Center at San Antonio
Last refreshed: 10 August 2021

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03397030.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing